Updated Jul 16, 2026
Worthington Mark is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $10K.
Mark Worthington serves as the General Counsel and Chief Compliance Officer at Athira Pharma, Inc., a biopharmaceutical company focused on neurodegeneration treatments. He has been involved in the company's regulatory and compliance matters, although specific details about his career prior to Athira are not widely documented.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-06 | LONA | LeonaBio, Inc. | S — Open-market sale | 1.3K | $5.37 | $7K |
| 2026-03-06 | LONA | LeonaBio, Inc. | M — Option exercise | 5.7K | $0.00 | |
| 2025-06-30 | LONA | LeonaBio, Inc. | S — Open-market sale | 8.5K | $0.29 | $3K |
| 2025-06-30 | LONA | LeonaBio, Inc. | M — Option exercise | 36.7K | $0.00 |
Mark Worthington serves as the General Counsel and Chief Compliance Officer at Athira Pharma, Inc., a biopharmaceutical company focused on neurodegeneration treatments. He has been involved in the company's regulatory and compliance matters, although specific details about his career prior to Athira are not widely documented.…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($10K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Worthington Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.